TransMedics Group, Inc.
TMDX- Exchange
- Nasdaq
- Industry
- Electromedical & Electrotherapeutic Apparatus
- SEC CIK
- 0001756262
In the last 90 days, TransMedics Group, Inc. insiders filed 1 open-market purchase and 0 sales; 375 institutions reported holding it in 13F filings for Q2 2026, worth $2.31B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by TransMedics Group, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 1 filing
- 1 insider, $109.1K in total
- Open-market sells
- 0 filings
- Insiders trading
- 1
- Net value
- +$109.1K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for TransMedics Group, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Weill David | Director | 16,392 | Sep 14, 2026 | 4 |
| Tobin James R | Director | 0Indirect | Aug 17, 2026 | 2 |
| Corcoran Nicholas | See remarks | 41,558 | Jul 14, 2026 | 2 |
| Hernandez Gerardo | Chief Financial Officer | 31,935 | Jul 14, 2026 | 3 |
| Hassanein Waleed H | President & CEO | 171,093 | Jul 14, 2026 | 2 |
| Gunderson Thomas James | Director | 16,642 | Jun 17, 2026 | 2 |
| Raines Merilee | Director | 6,981 | May 22, 2026 | 1 |
| Kania Edwin M Jr | Director | 263,732 | May 22, 2026 | 1 |
| Lovell Stephanie | Director | 5,788 | May 22, 2026 | 2 |
| Basile Edward M | Director | 5,788 | May 22, 2026 | 2 |
| Forsyth Matthew S. | See Remarks | 15,409 | May 21, 2026 | 1 |
| Ranganath Anil P. | See remarks | 13,091 | Mar 4, 2026 | 2 |
| Cecere Giovanni | Chief Commercial Officer | 19,057 | Feb 20, 2026 | 1 |
| Khayal Tamer I | Chief Commercial Officer | 36,042 | Mar 5, 2025 | 0 |
| Gordon Stephen | Chief Financial Officer | 21,299 | Jun 5, 2024 | 0 |
| Provost Miriam | VP, Global Regulatory Affairs | 23,348 | Dec 15, 2023 | 0 |
| Damme Laura | VP, Clinical Affairs | 5,685 | Feb 22, 2023 | 0 |
| Carey John F | VP of Operations | 14,120 | Feb 3, 2023 | 0 |
| Sullivan John F | VP of Quality & Engineering | 14,273 | Sep 1, 2021 | 0 |
| Godhani Rakesh P. | Chief Digital Officer | – | Aug 6, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 13, 2024 (view filing) | Nov 11 | 2 days | Khayal Tamer IChief Commercial Officer | SSale | −1.46K | $90.04 | −$131.3K | −6.5%20.8K after | 10b5-1 |
| Dec 4, 2024 (view filing) | Dec 2 | 2 days | Khayal Tamer IChief Commercial Officer | SSale | −1.08K | $86.40 | −$93.7K | −4.9%20.8K after | 10b5-1 |
| Jan 10, 2025 (view filing) | Jan 7 | 3 days | Khayal Tamer IChief Commercial Officer | SSale | −1.08K | $80.05 | −$86.7K | −4.9%20.8K after | 10b5-1 |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Khayal Tamer IChief Commercial Officer | SSale | −2.41K | $76.43 | −$184.0K | −6.3%36.0K after | |
| May 13, 2025 (view filing) | May 9 | 4 days | Basile Edward MDirector | SSale | −6.00K | $115.63 | −$693.8K | −89.1%732 after | 10b5-1 |
| May 23, 2025 (view filing) | May 23 | Same day | Weill DavidDirector | SSale | −732 | $123.88 | −$90.7K | −5.7%12.1K after | |
| May 29, 2025 (view filing) | May 27 | 2 days | Basile Edward MDirector | SSale | −5.00K | $126.45 | −$632.3K | −63.6%2.87K after | 10b5-1 |
| Jun 10, 2025 (view filing) | Jun 9 | 1 day | Ranganath Anil P.See remarks | SSale | −686 | $139.80 | −$95.9K | −4.7%14.0K after | |
| Aug 5, 2025 (view filing) | Aug 4 | 1 day | Basile Edward MDirector | SSale | −4.14K | $125.51 | −$520.0K | −59.1%2.87K after | 10b5-1 |
| Aug 8, 2025 (view filing) | Aug 6-7 | 2 days | Hassanein Waleed HPresident & CEO | PPurchase | +16.9K | $117.46 | +$1.98M | +3.6%486.2K after | 3 lots |
| Oct 31, 2025 (view filing) | Oct 29 | 2 days | Basile Edward MDirector | SSale | −4.14K | $130.45 | −$540.3K | −59.1%2.87K after | 10b5-1 |
| Nov 18, 2025 (view filing) | Nov 17 | 1 day | Hassanein Waleed HPresident & CEO | PPurchase | +8.78K | $114.00 | +$1.00M | +1.8%495.0K after | |
| Nov 26, 2025 (view filing) | Nov 25 | 1 day | Ranganath Anil P.See remarks | SSale | −3.00K | $145.22 | −$435.7K | −17.7%14.0K after | |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Hernandez GerardoChief Financial Officer | SSale | −920 | $139.62 | −$128.5K | −5.8%15.1K after | |
| Dec 5, 2025 (view filing) | Dec 3 | 2 days | Weill DavidDirector | SSale | −5.00K | $138.64 | −$693.2K | −29.2%12.1K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Corcoran NicholasSee remarks | SSale | −2.97K | $139.12 | −$412.6K | −9.0%29.8K after | |
| Mar 4, 2026 (view filing) | Mar 2 | 2 days | Ranganath Anil P.See remarks | SSale | −864 | $139.12 | −$120.2K | −6.2%13.1K after | |
| Mar 4, 2026 (view filing) | Mar 2-4 | 2 days | Hernandez GerardoChief Financial Officer | SSale | −7.61K | $146.81 | −$1.12M | −34.1%14.7K after | 3 lots |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Weill DavidDirector | SSale | −3.57K | $146.82 | −$524.3K | −22.7%12.1K after | |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Lovell StephanieDirector | SSale | −1.19K | $149.62 | −$178.5K | −29.4%2.87K after | |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Gunderson Thomas JamesDirector | SSale | −9.62K | $75.06 | −$722.4K | −36.6%16.6K after | |
| Sep 14, 2026 (view filing)4:30 PM ET | Sep 11 | 3 days | Weill DavidDirector | PPurchase | +1.34K | $81.63 | +$109.1K | +8.9%16.4K after |